{"id":"placebo-entecavir","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Lactic acidosis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Entecavir is a nucleoside analog that selectively inhibits HBV polymerase, blocking both reverse transcription and protein priming steps essential for viral DNA synthesis. It achieves high potency against HBV with minimal activity against human reverse transcriptases, making it selective for the viral enzyme. The placebo component in this formulation indicates a comparative study design.","oneSentence":"Entecavir inhibits hepatitis B virus reverse transcriptase and protein priming, reducing viral replication in chronic hepatitis B infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:43.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT05763576","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-28","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02065336","phase":"PHASE2","title":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2014-03","conditions":"Hepatitis B, Chronic","enrollment":58},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT04536337","phase":"PHASE1","title":"A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects","status":"COMPLETED","sponsor":"Aligos Therapeutics","startDate":"2020-10-22","conditions":"Chronic Hepatitis B","enrollment":165},{"nctId":"NCT02452528","phase":"PHASE2","title":"Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT07095855","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2025-08","conditions":"Chronic Hepatitis B","enrollment":1300},{"nctId":"NCT06990776","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects","status":"WITHDRAWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-07-09","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT05905172","phase":"PHASE3","title":"Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2023-08-12","conditions":"Liver Fibrosis","enrollment":248},{"nctId":"NCT02496897","phase":"PHASE1","title":"Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2015-07","conditions":"Hepatitis B","enrollment":61},{"nctId":"NCT04535544","phase":"PHASE2","title":"A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-17","conditions":"Hepatitis D, Chronic","enrollment":52},{"nctId":"NCT04129554","phase":"PHASE2","title":"A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-11-06","conditions":"Hepatitis B, Chronic","enrollment":130},{"nctId":"NCT03982186","phase":"PHASE2","title":"A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-08-01","conditions":"Hepatitis B, Chronic","enrollment":471},{"nctId":"NCT05423106","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Study of JNJ-64457744","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-04","conditions":"Healthy, Hepatitis B, Chronic","enrollment":60},{"nctId":"NCT05115942","phase":"PHASE3","title":"Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2021-12-30","conditions":"Liver Fibrosis","enrollment":248},{"nctId":"NCT05017116","phase":"PHASE1","title":"A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Suzhou Ribo Life Science Co. Ltd.","startDate":"2021-08-09","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT06150014","phase":"PHASE1, PHASE2","title":"A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-07","conditions":"Chronic Hepatitis b","enrollment":88},{"nctId":"NCT06566248","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-03-20","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT04536532","phase":"PHASE1, PHASE2","title":"Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study","status":"TERMINATED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2020-10-09","conditions":"Hepatitis B, Chronic","enrollment":52},{"nctId":"NCT05107778","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-01-10","conditions":"Hepatitis B, Chronic","enrollment":43},{"nctId":"NCT03905655","phase":"PHASE2","title":"Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2019-10-22","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT05808335","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)","status":"UNKNOWN","sponsor":"ImmuneMed, Inc.","startDate":"2022-01-11","conditions":"Chronic Hepatitis B","enrollment":32},{"nctId":"NCT05484466","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB","status":"UNKNOWN","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2022-11-11","conditions":"Hepatitis B, Chronic","enrollment":90},{"nctId":"NCT05391360","phase":"PHASE1","title":"Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-10-11","conditions":"Hepatitis B, Chronic","enrollment":128},{"nctId":"NCT05687409","phase":"PHASE4","title":"Synbiotics Interventions for Managing Cirrhosis and Its Complications","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2019-11-24","conditions":"Cirrhosis, Liver, Metagonimiasis","enrollment":120},{"nctId":"NCT03361956","phase":"PHASE2","title":"An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2018-02-13","conditions":"Hepatitis B","enrollment":232},{"nctId":"NCT04465916","phase":"PHASE2","title":"Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)","status":"TERMINATED","sponsor":"Enyo Pharma","startDate":"2020-05-12","conditions":"Hepatitis B, Chronic","enrollment":26},{"nctId":"NCT04454567","phase":"PHASE2","title":"A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2020-11-11","conditions":"Chronic Hepatitis B","enrollment":2},{"nctId":"NCT04398134","phase":"PHASE2","title":"A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2020-08-28","conditions":"Chronic Hepatitis B","enrollment":88},{"nctId":"NCT02499562","phase":"PHASE2","title":"A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis","status":"COMPLETED","sponsor":"Shanghai Genomics, Inc.","startDate":"2015-06-25","conditions":"Hepatitis B, Chronic","enrollment":168},{"nctId":"NCT04182321","phase":"NA","title":"Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Fu-Sheng Wang","startDate":"2020-03-13","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT03576066","phase":"PHASE2","title":"A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2018-06-11","conditions":"Chronic Hepatitis B","enrollment":73},{"nctId":"NCT03577171","phase":"PHASE2","title":"A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2018-06-19","conditions":"Chronic Hepatitis B","enrollment":25},{"nctId":"NCT02053727","phase":"NA","title":"Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2014-07","conditions":"Rheumatoid Arthritis, Chronic Hepatitis B","enrollment":""},{"nctId":"NCT02945956","phase":"PHASE4","title":"Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":192},{"nctId":"NCT02945982","phase":"PHASE4","title":"Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":184},{"nctId":"NCT04180150","phase":"PHASE2","title":"A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-11-18","conditions":"Chronic Hepatitis B","enrollment":12},{"nctId":"NCT01326546","phase":"PHASE2","title":"Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Chongqing Jiachen Biotechnology Ltd.","startDate":"2010-06","conditions":"Chronic Hepatitis B","enrollment":378},{"nctId":"NCT01079806","phase":"PHASE3","title":"A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-06-30","conditions":"Chronic Hepatitis B Virus, Pediatric","enrollment":180},{"nctId":"NCT02908191","phase":"PHASE1","title":"A Study in Healthy Volunteers and Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":86},{"nctId":"NCT02241590","phase":"PHASE4","title":"Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2014-09","conditions":"Liver Cirrhosis Due to Hepatitis B Virus","enrollment":700},{"nctId":"NCT03272009","phase":"PHASE1","title":"Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2017-09-21","conditions":"Hepatitis B, Chronic","enrollment":73},{"nctId":"NCT03109730","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2017-06-15","conditions":"Chronic Hepatitis B","enrollment":38},{"nctId":"NCT03239353","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects","status":"COMPLETED","sponsor":"Aucta Pharmaceuticals, Inc","startDate":"2017-10-20","conditions":"HBV","enrollment":40},{"nctId":"NCT02391805","phase":"PHASE2","title":"A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-17","conditions":"Hepatitis B, Chronic","enrollment":31},{"nctId":"NCT03349008","phase":"PHASE4","title":"Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Cttq","startDate":"2017-11-25","conditions":"Chronic Hepatitis b, Liver Inflammation","enrollment":480},{"nctId":"NCT01913431","phase":"PHASE4","title":"Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-09-12","conditions":"HBeAg-Positive Chronic Hepatitis B","enrollment":118},{"nctId":"NCT00922207","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05-07","conditions":"Hepatitis B, Chronic","enrollment":280},{"nctId":"NCT01694264","phase":"PHASE3","title":"Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2012-09-01","conditions":"Chronic Hepatitis B, Rheumatoid Arthritis, Ankylosing Spondylitis","enrollment":43},{"nctId":"NCT03062813","phase":"PHASE4","title":"Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN)","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2017-02-01","conditions":"Hepatitis B Virus Associated Nephrotic Syndrome","enrollment":112},{"nctId":"NCT01179594","phase":"PHASE4","title":"A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2010-09-18","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT01217632","phase":"PHASE2","title":"A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"Kyntra Bio","startDate":"2010-08","conditions":"Liver Fibrosis Due to Chronic Hepatitis B Infection","enrollment":114},{"nctId":"NCT01480284","phase":"PHASE3","title":"Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":"Hepatitis B, Chronic","enrollment":166},{"nctId":"NCT02288208","phase":"PHASE1","title":"Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B","status":"TERMINATED","sponsor":"TetraLogic Pharmaceuticals","startDate":"2014-11","conditions":"Hepatitis B","enrollment":7},{"nctId":"NCT02412319","phase":"PHASE4","title":"The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection","status":"UNKNOWN","sponsor":"Shineway Pharmaceutical Co.,Ltd","startDate":"2014-10","conditions":"HBeAg Positive Chronic Hepatitis B","enrollment":288},{"nctId":"NCT00393484","phase":"PHASE4","title":"A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-02","conditions":"Chronic Hepatitis B","enrollment":122},{"nctId":"NCT00298363","phase":"PHASE2","title":"Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-04","conditions":"Chronic Hepatitis B","enrollment":112},{"nctId":"NCT01833611","phase":"PHASE4","title":"Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2008-09","conditions":"Chronic Hepatitis","enrollment":130},{"nctId":"NCT00921180","phase":"PHASE4","title":"Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2007-02","conditions":"Hepatitis B, Chronic","enrollment":148},{"nctId":"NCT01026610","phase":"PHASE2","title":"Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-08","conditions":"Chronic Hepatitis B","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":68,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard Therapy","baraclude"],"phase":"marketed","status":"active","brandName":"Placebo & Entecavir","genericName":"Placebo & Entecavir","companyName":"Fu-Sheng Wang","companyId":"fu-sheng-wang","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Entecavir is a small molecule used to treat Chronic Hepatitis B, as indicated by ClinicalTrials.gov. It is administered orally in the form of a tablet, with Placebo being a comparison intervention in clinical studies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}